Ann: ACCENT Trial Recruitment Progress, page-17

While we focus on Pancreatic Cancer for this product , let's not forget NAFLD/ NASH is also being targeted .

https://pubmed.ncbi.nlm.nih.gov/32061595/ Nonalcoholic Fatty Liver Disease 2020 (USA): The State of the Disease "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population, respectively. Considering the ongoing obesity epidemic beginning in childhood, the rise in diabetes, and other factors, the prevalence of NAFLD along with the proportion of those with advanced liver disease is projected to continue to increase." - These figures would correlate to most Western based lifestyles. Huge upside here. GLTAH